165 results on '"Savill, A. M."'
Search Results
2. Biomarker testing and adjuvant osimertinib use in patients with resectable EGFR-mutated stage IB–IIIA NSCLC: Physician practices, therapy choice, and barriers among US oncologists.
3. Development of a novel methodology to assess response to lymphoma treatment in real-world data.
4. Distinct resistance mechanisms arise to allosteric vs. ATP-competitive AKT inhibitors
5. Real-world use of pemigatinib (pemi) for cholangiocarcinoma (CCA) among racial and ethnic minorities in the United States.
6. Characteristics, Treatment, and Outcomes of Real-World Talazoparib-Treated Patients With Germline BRCA-Mutated Advanced HER2-Negative Breast Cancer
7. Real-World Observational Study of Outcomes for Acute Myeloid Leukemia (AML) in Patients Treated with Glasdegib or Venetoclax in US Community Oncology Practices
8. Association of Clinical Characteristics at Diagnosis with Outcomes in Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated with Erythropoiesis Stimulating Agents (ESAs): Findings from a Real-World Medical Chart Review in the US
9. Myeloid/Lymphoid Neoplasms (MLNs) with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLNFGFR1): A US Real-World Retrospective Cohort Study
10. Real-World Outcomes of Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated with Luspatercept: An Evaluation of US Clinical Practice Utilization and Treatment Patterns
11. ABCL-207 Real-World Use of Tafasitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the United States by Primary Refractory Status
12. ABCL-206 Real-World Use of Tafasitamab for Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) in the United States by Age Group (>70 Years and ≤70 Years)
13. Real-World Use of Tafasitamab for Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) in the United States by Age Group (>70 Years and ≤70 Years)
14. Real-World Use of Tafasitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the United States by Primary Refractory Status
15. Real-world erythropoiesis-stimulating agent (ESA) treatment patterns and outcomes among U.S. patients with lower-risk myelodysplastic syndromes (LR-MDS).
16. Real-world utilization of ctDNA in the management of colorectal cancer.
17. Characteristics, Treatment, and Outcomes of Real-World Talazoparib-Treated Patients With Germline BRCA-Mutated Advanced HER2-Negative Breast Cancer.
18. Integrated CAD/CFD visualisation of a generic formula 1 car front wheel flowfield
19. Understanding Turbulence in Fluids using Direct Simulation Data
20. Novel Anti-LY6G6D/CD3 T-Cell–Dependent Bispecific Antibody for the Treatment of Colorectal Cancer
21. One-Point Closures Applied to Transition
22. Pattern Recognition Analysis of Structure in Manipulated Channel Flow Simulations
23. Evaluating Turbulence Model Predictions of Transition : An ERCOFTAC Special Interest Group Project
24. A Comparison of Turbulence Models for Homogeneous Shear Flows with Longitudinal Curvature
25. High resolution conformal mesh computations for V, U or L groove riblets in laminar and turbulent boundary layers
26. Manipulation and Modelling of Turbulent Pipe Flow: Some Parametric Studies of Single and Tandem Ring Devices
27. Drag Reduction by Passive Devices—a Review of some Recent Developments
28. Lower-Risk Myelodysplastic Syndromes: Erythropoiesis-Stimulating Agent Treatment Approaches and Outcomes in the United States
29. Real-World Treatment of Patients with Large B-Cell Lymphoma in the United States with Chimeric Antigen Receptor T-Cell Therapy
30. Persistence of Collagen Type II-Specific T-Cell Clones in the Synovial Membrane of a Patient with Rheumatoid Arthritis
31. External Intermittency Simulation in Turbulent Round Jets
32. Tafasitamab for the Treatment of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) in the US Real-World Setting
33. Real-World Use of Tafasitamab (tafa) for Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Among Racial and Ethnic Minorities in the United States
34. Racial disparity in uterine cancer treatment and survival: A matter of Black women’s lives.
35. Awareness and utilization of tumor mutation burden (TMB) as a biomarker for administration of immuno-oncology (I-O) therapeutics by practicing community oncologists in the United States (U.S.).
36. Strategies to investigate gene expression and function in granule cells
37. The mitogenic activity of fibronectin fragments
38. Guidelines and criteria for the use of turbulence models in complex flows
39. Experimental results on aerofoil manipulators at high subsonic speeds
40. A numerical investigation of aerofoil boundary-layer manipulator profile for cruise-flight conditions
41. Predicting Transition with Turbulence Models : The Effect of Varible Free-Sream Turbulence Length-Scale
42. A region of human BRCA2 containing multiple BRC repeats promotes RAD51-mediated strand exchange
43. Integrated CAD/CFD visualisation of a generic formula 1 car front wheel flowfield
44. Simulation and Modelling of Turbulent Trailing-Edge Flow
45. One-Point Closures Applied to Transition
46. Predicting Transition with Turbulence Models
47. The Application of a Laminar Flamelet Model to Confined Explosion Hazards
48. Evaluating Turbulence Model Predictions of Transition
49. Pattern Recognition Analysis of Structure in Manipulated Channel Flow Simulations
50. High resolution conformal mesh computations for V, U or L groove riblets in laminar and turbulent boundary layers
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.